Home
Tercica

Tercica Market Share Analysis for January 2026

Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.

Health > Biotechnology and Pharmaceuticals

Domainipsenus.com

Year Founded--

Employees501 - 1000

Annual Revenue--

Tercica

Tercica (including company regionals)

ipsenus.com

See more website traffic and engagement information

Total visits to Tercica's top domains

Understand Tercica market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Tercica's top domains

Analyze Tercica engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Tercica's top domains

See how Tercica keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Tercica top competitors by domain

Top similar sites in January 2026, ranked by their affinity

ipsen.comCompany NameIpsenEmployees5001 - 10000HQFrance, Boulogne-BillancourtAnnual revenue> $1BTotal visits112.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Tercica

These are the website technologies, by industry, used by Tercica top domains

Widget (4)

Twemoji

Conversion & Analytics (3)

Google Analytics

Advertising (2)

Twitter Advertiser

Audio Video Media (2)

YouTube

More Technologies

8

See all

News & Signals from Tercica

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsQuotient Sciences Limited partnered with Ipsen on Feb 26th '26.Philadelphia, PA - 26 February 2026 - Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

NewsOrigami Therapeutics, Inc. partnered with Ipsen on Jan 30th '26.SAN DIEGO - (BUSINESS WIRE) - Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder.

NewsIpsen attends event EASL Congress 2025.GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025.